By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Peripherally acting antiobesity agents > Orlistat > Orlistat Dosage
Peripherally acting antiobesity agents
https://themeditary.com/dosage-information/orlistat-dosage-6269.html

Orlistat Dosage

Drug Detail:Orlistat (Orlistat [ or-li-stat ])

Drug Class: Peripherally acting antiobesity agents

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Obesity

Prescription strength (Xenical[R]):
120 mg orally 3 times a day with each main meal containing fat

Non-prescription (over-the-counter; Alli[R]):
60 mg orally 3 times a day with each main meal containing fat

Comments:

  • This drug should be taken during, or up to 1 hour after meals; if a meal is skipped or contains no fat, the dose may be skipped.
  • Doses above 120 mg 3 times a day have not been shown to provide additional benefit.
  • During therapy, patients should receive a nutritionally balanced, reduced-calorie diet containing approximately 30% of calories from fat.

Uses: For the management of weight loss and weight maintenance when used in conjunction with a reduced calorie diet.

Usual Pediatric Dose for Obesity

12 years or older:
Prescription strength (Xenical[R]):
120 mg orally 3 times a day with each main meal containing fat

Comments:

  • This drug should be taken during, or up to 1 hour after meals; if a meal is skipped or contains no fat, the dose may be skipped.
  • Doses above 120 mg 3 times a day have not been shown to provide additional benefit; the over the counter orlistat product (Alli[R]) is not labeled for pediatric use.
  • During therapy, patients should receive a nutritionally balanced, reduced-calorie diet containing approximately 30% of calories from fat.

Uses: For the management of weight loss and weight maintenance when used in conjunction with a reduced calorie diet.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended

Dose Adjustments

Patients with diabetes mellitus:

  • Dose adjustment of diabetes medications may be necessary; monitor glycemic control closely

Precautions

CONTRAINDICATIONS:

  • Pregnancy
  • Chronic malabsorption syndrome
  • Cholestasis
  • Hypersensitivity to the active substance or any product excipients

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Take orally with each main meal containing fat; may take up to 1 hour after a meal
  • Dose may be skipped if a meal is missed or meal does not contain fat
  • A vitamin supplement that contains fat-soluble vitamins should be taken while taking this drug

Multivitamin: Take at least 2 hours before or after this drug (e.g. bedtime)
Cyclosporine: Take 3 hours before or after this drug; measure cyclosporine levels
Levothyroxine: Take at least 4 hours before or after this drug; monitor thyroid function

General:
  • This drug is intended for obese patients with an initial body mass index (BMI) of 30 kg/m2 or greater OR 27 kg/m2 in the presence of other risk factors such as hypertension diabetes, or dyslipidemia. The manufacturer's package insert can be consulted for BMI charts.
  • Substantial weigh loss can increase the risk of cholelithiasis.

Monitoring:
  • Monitor for signs and symptoms of hepatotoxicity; obtain liver function tests if these develop
  • Monitor renal function in patients at risk for renal impairment

Patient advice:
  • Patients should be instructed to adhere to a nutritionally balanced low-calorie diet that derives approximately 30% or less of its calories from fat; consuming higher amounts of fat may make the common side effects worse.
  • Patients should understand that they should not take this drug at the same time as their multivitamin; other drugs may need to be taken separately as well and they should speak with their healthcare professional regarding all concomitant medication use.
  • Patients should be instructed to immediately report signs and symptoms of hepatic dysfunction (e.g., itching, yellow eyes or skin, dark urine, or loss of appetite) or severe, continuous abdominal pain.
  • Patients should be instructed to report changes in glycemic control or seizure activity.
  • Patients should not take this drug if they are pregnant, breastfeeding, or have chronic malabsorption syndrome.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by